Clascoterone

Researchers found that the efficacy of clascoterone cream 1% for the treatment of acne vulgaris increased over time up to 12 months and thus recommend persistent treatment regimens for optimal results, according to a study.

In this edition, M-PDT efficacy similar to isotretinoin in acne vulgaris; Spitz neoplasm diagnosis in adults; immunotherapy treatment shows promise in basal cell carcinoma and more.

Clascoterone cream 1% may be a safe and effective alternative to traditional medications for the long-term treatment of acne vulgaris in patients aged 12 years and older, according to a phase 3 extension trial.

MIAMI BEACH, Fla. — Clascoterone cream 1% demonstrated long-term efficacy and a favorable safety profile in patients aged older than 12 years with acne vulgaris, according to extension study results presented here.

BOSTON — Treatment with clascoterone cream effectively treated facial acne vulgaris among patients aged 12 years and older, according to a poster presented at the American Academy of Dermatology Annual Meeting.